About the BURDEN survey and the Rosacea: Beyond the visible online report The BURDEN survey was developed by Kantar Health as a self-administered online survey and supported by Galderma. Participants were recruited using the Kantar online panel. To maximize the sample size no quota was set up. Therefore, the sample is not representative of the rosacea population of each country; consequently, the results of this study could be affected by selection bias and cannot be inferred to the whole rosacea population. Rosacea: Beyond the visible was developed under the direction and sponsorship of Galderma International, survey was conducted by Kantar Health with writing support provided by Emma Waring, Havas Life Medicom.
About Rosacea Rosacea is a common inflammatory skin disease that presents variable clinical characteristics, of which the most common are flushing, permanent erythema, and inflammatory lesions. It mainly affects the central areas of the face, such as the cheeks and nose. The disease can affect both adult men and women, usually after the age of 30. Additionally, symptoms such as stinging, burning and increased sensitivity of the skin are common. The eyes are often affected, and might present as red, dry or itchy.
Although the cause of the disease is still under debate, various trigger factors are known, including spicy foods, alcohol, emotional stress, sun/UV-exposure, hot baths and beverages. Demodex, generally harmless mites, can also be found in the skin in an elevated quantity in people with rosacea.
Rosacea may worsen over time if left untreated. People that suspect they suffer from rosacea should visit their dermatologist or healthcare provider for diagnosis and discuss what treatment is right for them. Because rosacea is a highly visible disease, it is known to cause embarrassment and anxiety in some patients, which in turn may cause frustration and have a negative impact on their social life.
About Galderma Galderma, Nestle Skin Health's medical solutions business, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit http://www.galderma.com
1) Rosacea: Beyond the visible online report, BMJ Hosted Website (http://hosted.bmj.com/rosaceabeyondthevisible). Last accessed: June 2018 2) Shanler S, Ondo A. Successful treatment of the erythema and flushing of rosacea using a topically applied selective a1 adrenergic receptor agonist, oxymetazoline [abstract taken from J Am Acad Dermatol. 2008;58(2): AB9]. Presented at: American Academy of Dermatology 66th Annual Meeting; February 1-5, 2008; San Antonio, TX 3) Webster G et al. J Dermatolog Treat. 2017;28(5):469-474
(Logo: http://mma.prnewswire.com/media/554005/Galderma_Logo.jpg )
CONTACT: Galderma media relations contact: Sébastien Cros, GlobalCommunications, +41-21-642-76-94, firstname.lastname@example.org